Dogwood Therapeutics (NASDAQ:DWTX) Posts Earnings Results, Beats Expectations By $0.07 EPS

Dogwood Therapeutics (NASDAQ:DWTX) announced its earnings results on Thursday. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07, Zacks reports.

Dogwood Therapeutics Trading Up 4.8%

Shares of DWTX traded up $0.09 during mid-day trading on Thursday, reaching $1.95. The company’s stock had a trading volume of 70,674 shares, compared to its average volume of 80,073. Dogwood Therapeutics has a 1-year low of $1.28 and a 1-year high of $9.50. The business has a 50-day simple moving average of $2.14 and a two-hundred day simple moving average of $3.68. The stock has a market cap of $65.13 million, a P/E ratio of -0.10 and a beta of 1.68.

Hedge Funds Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. 9.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on DWTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a research report on Monday, April 27th. Weiss Ratings downgraded Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Dogwood Therapeutics currently has a consensus rating of “Hold” and an average price target of $12.00.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical?stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high?throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.